For those folks following the saga of the $750-per-dose Daraprim kerfluffle, there's been a rather dramatic new development:
Now that's a bargain!
And it proves (again) the power of the free market. In fact, the company plans to expand this effort to other "sole-source generic" meds. So the market self-corrects without heavy-handed government intervention.
Gee, wonder if this could apply to other sectors, as well.
Now that's a bargain!
And it proves (again) the power of the free market. In fact, the company plans to expand this effort to other "sole-source generic" meds. So the market self-corrects without heavy-handed government intervention.
Gee, wonder if this could apply to other sectors, as well.